Skip to main content
. 2017 Jan 31;8(29):46915–46927. doi: 10.18632/oncotarget.14911

Figure 5. Determination of anti-proliferative and cytotoxic effects of Vandetanib in combination with the PI3K inhibitor GDC-0941.

Figure 5

Medulloblastoma cells were treated with 2 μM of Vandetanib or 1 μM of the PI3K inhibitor GDC-0941 alone or in combination for 48h. Viable cell number A. cell death B. and inhibition of proliferation C. was analysed by flow cytometry following a CFSE/Hoechst 33258 stain. DMSO was used as control. Inhibition of proliferation was normalized to control DMSO and all stated values differ significantly (p<0.05) from the control DMSO. Other values tagged with a hashsign also differ significantly from the control (#p<0.05), while all values tagged with an asterisk differ significantly from single drug application (*p<0.05). The data shown represent four independent experiments.